retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide Shows Promising Results in

DAscanio AM, Mullally JA, Frishman WH

Stay Hydrated : Sipping water or ginger tea can help settle your stomach

Learn about Retatrutide (GGG tri-agonist) medication Retatrutide is an up and coming medication, still in clinical trials and does not yet have a known time when it will be approved for use or available to the general public

To date, liraglutide, and the more effective once-weekly semaglutide, have been approved in the US and Europe for the treatment of obesity, with unprecedented weight loss of up to 1520%

It supports digestion, prevents dehydration from diarrhea episodes, and helps maintain regular bowel movements

Despite the limitations, these data suggest that long term therapy is not associated with durable weight loss with withdrawal of the medication and supports guidelines for extended therapy